文献速递糖尿病

糖尿病类型内部与类型之间异质性的临床后果

The clinical consequences of heterogeneity within and between different diabetes types.
PubMed 文献 · Diabetologia · 2020-09-07

本文综述分子方法和大规模人群数据共享所揭示的糖尿病类型内部异质性及类型间共性。1型糖尿病已基于人口学、遗传、免疫、组织病理、代谢及临床病程特征发现内型;2型糖尿病中胰岛素抵抗与β细胞功能障碍的相对贡献异质,并与人口学、遗传及临床特征相关。文章讨论单基因糖尿病作为精准医学范例,以及异质性对经典分类框架的挑战与「调色板模型」「阈值假说」的解释作用。

要点

  • 1型糖尿病可依据人口学、遗传、免疫、病理及代谢特征划分内型,影响预测、预防、诊断与治疗。
  • 2型糖尿病中胰岛素抵抗与β细胞功能障碍的相对贡献异质,受人口学、遗传、环境暴露及临床特征影响。
  • 单基因糖尿病因突变基因影响表型与治疗,是精准医学的范例,但其与1型、2型特征重叠使诊断困难。

核心结论

  • 糖尿病类型内部与类型之间存在异质性,经典分类框架面临挑战,需结合「调色板模型」与「阈值假说」等新思路推进精准医学。

研究设计与样本

  • 综述类文章,检索范围涉及分子方法进展、大规模人群数据集共享以及糖尿病异质性相关研究。

主要发现

  • 1型糖尿病已基于人口学(如诊断年龄、种族/民族)、遗传、免疫、组织病理、代谢和/或临床病程特征发现内型。
  • 2型糖尿病中胰岛素抵抗与β细胞功能障碍的相对贡献异质,并与人口学、遗传和临床特征相关,同时受环境暴露的实质性交互影响。
  • 研究者提出从简单到复杂的方法,将这些数据组合以识别与预后和治疗相关的2型糖尿病聚类。
  • 药物遗传学和药物动力学进展也在改善治疗。
  • 异质性模糊了糖尿病类型间的经典区分,促成成人隐匿性自身免疫糖尿病、1.5型糖尿病和酮症倾向糖尿病等额外类别的定义。

临床怎么用

  • 临床应认识到同一糖尿病类型内存在异质的内型或聚类,诊疗需结合人口学、遗传、免疫及代谢特征进行个体化评估。
  • 单基因糖尿病的确诊依赖于明确突变基因,因其表型与治疗随突变基因而异,且与1型、2型特征重叠,诊断时需警惕。

局限性

  • 本文为综述,未报告具体研究样本量、效应值或阈值等定量数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Advances in molecular methods and the ability to share large population-based datasets are uncovering heterogeneity within diabetes types, and some commonalities between types. Within type 1 diabetes, endotypes have been discovered based on demographic (e.g. age at diagnosis, race/ethnicity), genetic, immunological, histopathological, metabolic and/or clinical course characteristics, with implications for disease prediction, prevention, diagnosis and treatment. In type 2 diabetes, the relative contributions of insulin resistance and beta cell dysfunction are heterogeneous and relate to demographics, genetics and clinical characteristics, with substantial interaction from environmental exposures. Investigators have proposed approaches that vary from simple to complex in combining these data to identify type 2 diabetes clusters relevant to prognosis and treatment. Advances in pharmacogenetics and pharmacodynamics are also improving treatment. Monogenic diabetes is a prime example of how understanding heterogeneity within diabetes types can lead to precision medicine, since phenotype and treatment are affected by which gene is mutated. Heterogeneity also blurs the classic distinctions between diabetes types, and has led to the definition of additional categories, such as latent autoimmune diabetes in adults, type 1.5 diabetes and ketosis-prone diabetes. Furthermore, monogenic diabetes shares many features with type 1 and type 2 diabetes, which make diagnosis difficult. These challenges to the current classification framework in adult and paediatric diabetes require new approaches. The 'palette model' and the 'threshold hypothesis' can be combined to help explain the heterogeneity within and between diabetes types. Leveraging such approaches for therapeutic benefit will be an important next step for precision medicine in diabetes. Graphical abstract.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Redondo MJ, Hagopian WA, Oram R, et al. The clinical consequences of heterogeneity within and between different diabetes types. Diabetologia. 2020. PMID: 32894314. doi:10.1007/s00125-020-05211-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。